<div id="readability-page-1"><p><span>X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report)</span> was downgraded by equities researchers at Zacks Research from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a note issued to investors on Wednesday,Zacks.com reports.</p><p>A number of other research firms have also commented on XFOR. Stifel Nicolaus  set a $7.50 price objective on X4 Pharmaceuticals in a research note on Wednesday, November 5th. Wall Street Zen upgraded shares of X4 Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, November 22nd. HC Wainwright  set a $3.50 price target on shares of X4 Pharmaceuticals and gave the company a &#34;buy&#34; rating in a research note on Wednesday, August 13th. Finally, Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of X4 Pharmaceuticals in a report on Monday. Three analysts have rated the stock with a Buy rating, one  has assigned  a Hold rating and one  has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of &#34;Hold&#34; and a consensus price target of $33.67.</p><div><p><span></span><span>Get <strong>X4 Pharmaceuticals</strong> alerts:</span></p></div><p><b>Check Out Our Latest Research Report on X4 Pharmaceuticals</b></p><h2>X4 Pharmaceuticals Trading Up 1.1%</h2><p>Shares of XFOR opened at $3.68 on Wednesday. The company has a current ratio of 5.65, a quick ratio of 5.48 and a debt-to-equity ratio of 1.23. The stock has a market cap of $321.78 million, a PE ratio of -0.36 and a beta of 0.51. X4 Pharmaceuticals has a 1 year low of $1.35 and a 1 year high of $26.83. The stock has a 50 day simple moving average of $3.52 and a 200-day simple moving average of $2.98. </p><p>X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last announced its earnings results on Wednesday, November 5th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.79) by $0.10. The business had revenue of $1.77 million during the quarter, compared to analysts' expectations of $2.05 million. X4 Pharmaceuticals had a negative net margin of 279.86% and a negative return on equity of 343.67%.  On average, sell-side analysts predict that  X4 Pharmaceuticals will post -0.68 EPS for the current fiscal year. </p><h2>Insider Activity</h2><p>In related news, Chairman Adam R. Craig acquired 86,206 shares of the firm's stock in a transaction that occurred on Thursday, October 23rd. The stock was acquired at an average cost of $2.90 per share, with a total value of $249,997.40. Following the completion of the purchase, the chairman directly owned 376,087 shares in the company, valued at approximately $1,090,652.30. This trade represents a 29.74% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at the SEC website. 2.37% of the stock is owned by corporate insiders. </p><h2>Hedge Funds Weigh In On X4 Pharmaceuticals</h2><p>Several institutional investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. raised its holdings in  X4 Pharmaceuticals by 9.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 481,528 shares of the company's stock worth $114,000 after acquiring an additional 43,320 shares in the last quarter.  Pale Fire Capital SE raised its stake in shares of  X4 Pharmaceuticals by 45.2% during the 1st quarter. Pale Fire Capital SE now owns 2,035,362 shares of the company's stock worth $481,000 after purchasing an additional 633,398 shares in the last quarter.  Kingdon Capital Management L.L.C. boosted its holdings in shares of  X4 Pharmaceuticals by 41.8% in the 1st quarter. Kingdon Capital Management L.L.C. now owns 7,000,000 shares of the company's stock valued at $1,655,000 after buying an additional 2,063,000 shares during the last quarter.  Acorn Capital Advisors LLC boosted its holdings in shares of  X4 Pharmaceuticals by 77.8% in the 3rd quarter. Acorn Capital Advisors LLC now owns 273,349 shares of the company's stock valued at $935,000 after buying an additional 119,619 shares during the last quarter.  Finally, Boothbay Fund Management LLC bought a new position in shares of  X4 Pharmaceuticals in the third quarter valued at $1,176,000. Institutional investors own  72.03% of the company's stock. </p><h2>X4 Pharmaceuticals Company Profile</h2> (Get Free Report)<p>X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than X4 Pharmaceuticals</li><li>Unveiling The Power Of VWAP: A Key Indicator For Traders</li><li>MarketBeat Week in Review – 11/24 - 11/28</li><li>Diversification Can Smooth Returns And Mitigate Portfolio Risk</li><li>Power On: Applied Digital’s First AI Data Center Goes Live</li><li>What Does a Stock Split Mean? </li><li>Alphabet: The AI Leader Best Positioned to Dominate 2026</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEZPUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEZPUg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in X4 Pharmaceuticals Right Now?</h2><p>Before you consider X4 Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and X4 Pharmaceuticals wasn't on the list.</p><p>While X4 Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

XFOR

<p>Zacks Research downgraded X4 Pharmaceuticals (NASDAQ:XFOR) from a "strong-buy" to a "hold" rating. Other analysts have mixed ratings, with an average rating of "Hold" and a consensus price target of $33.67. The stock opened at $3.68 on Wednesday. X4 Pharmaceuticals reported a Q3 EPS of ($0.69), beating estimates by $0.10. Institutional investors own 72.03% of the stock.</p>

X4 Pharmaceuticals (NASDAQ:XFOR) Stock Rating Lowered by Zacks Research